Batch of medication capsules withdrawn due to possible metal contamination: what patients should do

rss · Infobae 2026-11-17T18:01:47Z es
Breckenridge Pharmaceutical announced the voluntary recall of a lot of 60 mg extended-release propranolol hydrochloride capsules in the United States, due to possible metal contamination. The company warned that consuming the affected product could cause injuries to the soft tissues of the mouth, esophagus, stomach, or intestine. The alert is related to a problem detected during the manufacturing process of the medications. Although it was not confirmed that all units sold contain metal particles, the company decided to recall the product as a precautionary measure to reduce the risk of consumer exposure. The measure covers units distributed to wholesalers and pharmacies nationwide. The company asked those who have purchased the medication to check the information on the packaging and follow the established instructions to avoid consuming the affected capsules. How to identify whether the packaging is part of the recall The recall covers 60-milligram extended-release propranolol hydrochloride capsules, sold in bottles of 100 units. According to the Breckenridge Pharmaceutical statement, the product was manufactured by Adare Pharma Solutions and distributed to wholesalers and pharmacies between October 26 and November 4, 2026. To determine whether a package is included in the alert, consumers should check the information printed on the contai…
Breckenridge Pharmaceutical announced the voluntary recall in the United States of a batch of 60 mg Propranolol Hydrochloride capsules due to possible metal presence. (Illustrative Image Infobae) Breckenridge Pharmaceutical announced the voluntary recall of a batch of 60 mg extended-release Propranolol Hydrochloride capsules in the United States, due to possible metal contamination. The company warned that consuming the product involved could cause soft tissue injuries in the mouth, esophagus, stomach, or intestines. The alert relates to a problem detected during the manufacturing process. Although it was not confirmed that all marketed units contain metallic particles, the company decided to withdraw the product as a preventive measure to reduce consumer exposure risk. The measure applies to units distributed to wholesalers and pharmacies nationwide. The company asked those who purchased the medication to check the packaging information and follow the established instructions to avoid consuming the involved capsules. The recall covers 60-milligram extended-release Propranolol Hydrochloride capsules, marketed in bottles of 100 units. According to Breckenridge Pharmaceutical's statement, the product was manufactured by Adare Pharma Solutions and distributed to wholesalers and pharmacies between October 26 and November 4, 2026. To determine if a package is included in the alert, consumers must review the printed data on the container. The identification provided by the company is as follows: Medication: Propranolol Hydrochloride Extended-Release Capsules, USP. Concentration: 60 milligrams. Presentation: bottle of 100 capsules. National Drug Code (NDC): 51991-817-01. Lot Number: PK25110035. Expiration Date: May 2029. The NDC allows identification of the commercial presentation of the medication, while the lot number is the data that allows distinguishing the units involved in this recall. Therefore, it is not enough to verify that the package contains 60-milligram propranolol; it is also necessary to verify that the code and, especially, the lot number indicated by the pharmaceutical company match. The warning does not cover all presentations of propranolol or all medications marketed by Breckenridge Pharmaceutical. The measure is limited to the 60 mg extended-release capsules corresponding to lot PK25110035. The alert covers the 100-unit bottles with NDC 51991-817-01, lot number PK25110035, and expiration date in May 2029. (Illustrative Image Infobae) The company warned that consuming the capsules from the affected lot could cause lacerations in the soft tissues of the oral cavity, esophagus, stomach, or intestines. The risk is related to the possible presence of metallic material in the product, which could cause injuries during its passage through the digestive system. According to Breckenridge Pharmaceutical, the marketed lot shared intermediate material with another lot in which a presumed source of metallic contamination was identified. This second product did not reach the market. The relationship between the two lots motivated the decision to recall the capsules that were indeed delivered to wholesalers and pharmacies. The company considered it necessary to adopt this measure because they shared material used during the manufacturing process, although the statement does not establish that all marketed units are contaminated. The pharmaceutical company noted that, up to the publication of the notice, it had no knowledge of adverse events evaluated as related to the recall. This means they had not reported cases they considered linked to this measure, although they maintain the warning about the possible damage the product could cause. The voluntary recall seeks to prevent consumers from continuing to use the potentially compromised units while the identified manufacturing problem is addressed. Breckenridge Pharmaceutical's main recommendation is that consumers immediately stop taking the capsules belonging to lot PK25110035 and contact their doctor or healthcare professional for instructions on medication substitution. This consultation allows patients to know how to continue treatment and what alternative they should use. Furthermore, those who have unused units should return them to the pharmacy where they purchased the product. This instruction applies to any remaining quantity of the medication included in the recall. In case of experiencing any problem that may be related to consuming the capsules, patients must contact a healthcare professional. They can also report possible adverse reactions or quality inconveniences through MedWatch, the U.S. Food and Drug Administration (FDA) program. According to the FDA, this system allows receiving reports on problems associated with medications and other medical products. Consumers and healthcare professionals can use it to communicate undesirable effects or possible quality failures, including suspected contamination. Breckenridge's recall is conducted with the knowledge of the U.S. regulatory authority. However, the company is responsible for the announcement and the specific instructions communicated to consumers. The affected lot shared intermediate material during manufacturing with another lot where a presumed source of metallic contamination was identified. (Illustrative Image Infobae) The instructions also apply to wholesalers, pharmacies, and other commercial establishments that received the capsules before the alert was published. Breckenridge asked them to review their inventories to identify units corresponding to lot PK25110035. Once the product is located, the establishments must separate the affected units, keep them out of circulation, and prevent their distribution or delivery to patients. This measure aims to prevent the bottles from continuing to reach consumers while the recovery procedure is underway. The company also indicated that entities that received the medication and subsequently distributed it must notify their own clients down to the retail level. In this way, establishments that may have acquired the capsules can identify the lot and adopt the corresponding measures. To address inquiries related to the recall, Breckenridge designated Qualanex as the service provider in charge of managing the procedure. Consumers, pharmacies, and distributors can contact them through the following channels: Phone: 1-855-736-0807. Email: recall@qualanex.com. Hours: Monday to Friday, 9 a.m. to 5 p.m., Eastern Time, USA. The statement was published on November 16, 2026, from Berkeley Heights, New Jersey. The company did not establish an end date for the recall nor specify how many units must be recovered.

Translated from es by z-ai/glm-5.3-flash

Knowledge Graph

Entities
Highlight